Very strong statistical significance. 3 weeks until first read out of phase 1 cohort. 18 million market cap on a 60 billion dollar unmet market and the only drug in the world to have this type of effectiveness in secondary brain injury preclinically
Ann: Significant Neuroprotection in Traumatic Brain Injury Study, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.025(10.0%) |
Mkt cap ! $47.45M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 22.5¢ | $209.3K | 892.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7150 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 416666 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |